1-2 of 2
Fadhela Bouafia, MD
Close
Sort by
Journal Articles

Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma

Marie-Charlotte Laude, Edith Julia, Emmanuelle Nicolas-Virelizier, MD, Gabriel Antherieu, Violaine Safar, Philippe Rey, MD, Emmanuelle Ferrant, MD, Alexandra Traverse-Glehen, MD PhD, Catherine Chassagne-Clément, MD, David Meyronet, MD PhD, Anne Lazareth, MD, Helene Lequeu, MD, Camille Golfier, MD, Gabriel Brisou, MD, Dana Ghergus, MD, Pierre Sesques, MD, Lionel Karlin, MD, Gilles Salles, MDPhD, Emmanuel Bachy, MD PhD, François Ducray, MD PhD, Fadhela Bouafia, MD, Youenn Drouet, PhD, Herve Ghesquieres, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
https://doi.org/10.1182/blood-2020-138789
Published: 2020
Journal Articles

Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

Gabriel Antherieu, PhD, Edith Julia, Emmanuelle Nicolas-Virelizier, MD, Marie-Charlotte Laude, Violaine Safar, Philippe Rey, MD, Emmanuelle Ferrant, MD, Alexandra Traverse-Glehen, MD PhD, Catherine Chassagne-Clément, MD, David Meyronet, MD PhD, Anne Lazareth, MD, Helene Lequeu, MD, Camille Golfier, MD, Gabriel Brisou, MD, Dana Ghergus, MD, Pierre Sesques, MD, Lionel Karlin, MD, Fadhela Bouafia, MD, Gilles Salles, MDPhD, Emmanuel Bachy, MD PhD, François Ducray, MD PhD, Youenn Drouet, PhD, Herve Ghesquieres, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-139946
Published: 2020